Market News AIOpen the app

Ovid Therapeutics shared updates on its research programs at the UBS Global Biopharma Conference, showing progress on its epilepsy treatment.

TrialRead the original at newsfilter.io
Neutral

Ovid shared planned study dates, but reported no trial results; the update does not show whether its treatments work. Its listed Q1 2026 OV329 readout date had passed by the conference, and Ovid has no active product sales.

OVID · Ovid Therapeutics

AI read · Neutral

The AI's read

The dates give Ovid milestones to watch, but they do not show whether either treatment helps patients. The listed Q1 2026 OV329 readout date had already passed by the conference, and no result was reported. Ovid also said it has no active product sales.

Get alerts for OVID

Follow Ovid Therapeutics (OVID) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for OVID
Free on the App Store and Google Play, or on the web.